6 January 2014 Business
Pharmaceutical industry roundup 2013
With the closure of the Horsham site Novartis only has one remaining R&D site in the UK © Novartis
The Horsham site was downsized back in 2011, when manufacturing and global development at the site were closed and gastrointestinal research was moved to Basel, Switzerland. The 2011 job losses at Horsham preceded a much larger swathe of job cuts at Novartis, with over 2000 jobs cut in Switzerland and the US in an attempt to improve productivity and absorb pricing pressures in Europe.
In a statement the company explained that it ‘continually evaluates its resource allocation to ensure that the organisation is highly flexible and able to proactively adapt to external challenges to best meet the needs of patients and customers. Our pipeline and future potential growth are strong. However, we face challenges in today’s industry.’
The Novartis statement added that the decision will be subject to an employee consultation process and final approval by the company’s UK board. After the closure of Horsham the company will continue to operate a number of UK manufacturing sites, as well as a team in Sittingbourne, Kent, that develops patient diagnostic tests.
1 February 2016 News and Analysis
A blanket ban on New Psychoactive Substances has been given final approval and will come into force in April
29 January 2016 News and Analysis
A technological leap may be called for to expand the number of elements in existence